Drug Profile
Research programme: hepatitis C virus polymerase inhibitors - Medivir/Janssen R&D Ireland
Alternative Names: HCV POL discovery project - Medivir/Janssen R&D IrelandLatest Information Update: 28 Dec 2015
Price :
$50
*
At a glance
- Originator Medivir AB
- Developer Janssen Infectious Diseases BVBA; Medivir AB
- Class Nucleosides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C